31 / 46
mCRPC patients
Main oncogenic events
AR
gain
AR
mutation
BRCA2
mutations
MMR defects
Other/unknown
ctDNA alterations
BRCA2
mutation
AR gain
Novel drivers
ctDNA alterations
AR
(p.T878A)
AR
(p.L702H)
AR
(p.W742C)
ATM
mutations
Other HR defects TP53
defects
PI3K pathway defects
E. González Billalabeitia. PCAN 2018